STOCK TITAN

Heartbeam Inc - BEAT STOCK NEWS

Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.

Overview of HeartBeam Inc

HeartBeam Inc (BEAT) is a pioneering medical technology company that specializes in the development and commercialization of high-resolution ambulatory Electrocardiogram (ECG) solutions. Leveraging innovative mHealth technology and cloud-based diagnostic expert systems, HeartBeam has established a robust platform capable of providing diagnostic quality equivalent to that of a traditional, in-clinic 12-lead ECG. The company employs a credit card–sized ECG device designed for ease of use and portability, which allows for immediate and accurate cardiac diagnostics outside a hospital setting. Its core technology integrates proprietary Vector Electrocardiography (VECG) with advanced artificial intelligence and machine learning, ensuring a continuously evolving diagnostic precision.

Technological Innovation and Diagnostic Accuracy

At the heart of HeartBeam’s mission is the objective to bring comprehensive cardiac diagnostics to a broader population through accessible technology. The company’s device, which is both compact and sophisticated, utilizes a 12-lead equivalent ECG monitoring system combined with a cloud-based expert system. Studies designed by Harvard Medical School faculty have demonstrated that the performance of this system is on par with, and in some cases exceeds, the diagnostic accuracy typically achieved by world-class cardiologists. Furthermore, the system’s use of personalized diagnostic thresholds and novel heart attack ECG markers underpins its utility in helping cardiologists accurately locate areas of cardiac distress on a 3D heart model, offering enhanced clinical insights.

Integrated AI and Machine Learning Capabilities

One of the distinctive aspects of HeartBeam’s technology is its integration of artificial intelligence and machine learning techniques. These technologies drive the continuous improvement of the system’s ability to analyze patient ECG data with a level of detail that aligns with high-resolution diagnostic standards. This approach not only supports more accurate and dynamic patient assessments but also reinforces the platform’s reliability through iterative learning and refinement of its predictive capabilities. The application of AI/ML is central to transforming raw cardiac data into actionable diagnostic insights, and it positions HeartBeam as a significant contributor in the realm of digital health innovation.

Market Position and Competitive Landscape

Within the competitive landscape of medical diagnostics and telehealth, HeartBeam Inc differentiates itself through its unique combination of compact hardware and sophisticated analytical software. The company’s pursuit of regulatory clearances, such as from the U.S. Food and Drug Administration (FDA), is a testament to its commitment to safety, reliability, and comprehensive diagnostic functionality. By addressing the discrepancy between traditional in-clinic diagnosis and the need for accessible, portable solutions, HeartBeam creates a niche within the cardiac monitoring market that is both innovative and crucial for modern healthcare practices.

Key Features and Business Model

  • High-Resolution Ambulatory ECG Devices: Compact devices that deliver hospital-grade diagnostics, supporting remote monitoring and telehealth.
  • Cloud-Based Diagnostic Systems: Seamlessly integrates with digital platforms to provide real-time analysis and expert reviews of cardiac data.
  • Proprietary Vector ECG Technology: Ensures enhanced clarity and precision in ECG readings, crucial for accurate diagnosis.
  • Artificial Intelligence Integration: Utilizes machine learning algorithms to adapt and improve diagnostic accuracy over time.
  • Clinical Validation: Supported by studies from Harvard Medical School, ensuring that the technology meets rigorous diagnostic standards.

Expertise and Trustworthiness

The comprehensive design and execution of HeartBeam’s solutions reflect a deep understanding of cardiac diagnostics and medical technology innovation. Industry-specific methodologies and a focus on data-driven decision making underscore the company’s expertise. By continuously refining its platform based on clinical insights and user feedback, HeartBeam not only builds trust among healthcare professionals but also positions itself as a valuable resource in the realm of digital cardiology.

Conclusion

In summary, HeartBeam Inc stands out by merging the highest standards of diagnostic accuracy with the practicality and convenience of portable mHealth solutions. This balance of technological sophistication and clinical relevance ensures that it remains an important player in the field of cardiac diagnostics. The company’s strategic focus on integrating advanced AI with proven ECG technology offers a reliable pathway for enhancing patient outcomes and expanding access to critical cardiac care in diverse settings.

Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) announced an expansion of its clinical validation study to include a broader patient population for its emergency department software technology. The decision follows the recent AHA guidelines and aims to include unstable angina patients, which may enhance heart attack detection. HeartBeam plans to file a 510K submission by August 15, 2022, which remains unaffected by the Telehealth product's timeline, scheduled for Q4 2022. This expanded scope aligns with their goal of improving cardiovascular diagnosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.84%
Tags
none
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT), a digital healthcare innovator, will present at the LD Micro Invitational XII Conference from June 7-9, 2022, in Westlake Village, CA. CFO Rick Brounstein and CBO Jon Hunt, PhD, will host 25-minute meetings and deliver a presentation on June 7 at 4:00 pm ET. HeartBeam specializes in proprietary ECG telemedicine technology aimed at improving heart attack detection outside medical institutions. This significant advancement addresses the high-risk cardiovascular patient population's needs. For more details, visit ir.heartbeam.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
conferences
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) will participate virtually in the H.C. Wainwright Global Investment Conference from May 23 – 26, 2022.

The company's CEO, Branislav Vajdic, CFO Rick Brounstein, and CBO Jon Hunt will conduct one-on-one meetings during the event. Jon Hunt will also deliver a virtual presentation available on-demand starting May 24, 2022.

This innovative digital healthcare company focuses on ECG telemedicine technology for heart attack detection, providing significant advancements in diagnosing cardiovascular diseases outside medical institutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.93%
Tags
conferences
Rhea-AI Summary

HeartBeam, a digital healthcare company (NASDAQ: BEAT), reported its Q1 2022 results, highlighting a net loss of $2.1 million, up from $210,000 in Q1 2021. R&D expenses increased significantly to $734,000, compared to $29,000 in the prior year. The company remains on track for an FDA submission for its Emergency Department Myocardial Infarction software in Q2 2022 and a Telehealth solution in Q4 2022. With cash reserves of $11.2 million, HeartBeam anticipates a full commercial rollout of its ED Software Tool in Q1 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
-
Rhea-AI Summary

The acquisition of RedCrow by Alira Health aims to enhance access to alternative investments in healthcare startups. Founded in 2016, RedCrow has raised $250 million through over 250 fundraises. This strategic move allows Alira to extend its patient engagement mission by involving them in the financing of new healthcare solutions. The financial terms of the acquisition remain undisclosed, but the collaboration is expected to democratize healthcare investing, promoting innovation in early-stage pharma and MedTech.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.6%
Tags
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) announces a conference call on May 12, 2022 at 4:30 p.m. Eastern time, to discuss its first-quarter results for the period ending March 31, 2022. The call will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt. Participants can join via telephone or webcast. A replay will be available until July 12, 2022. HeartBeam specializes in digital healthcare technology for heart attack detection using an innovative ECG device. For further details, visit www.heartbeam.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.3%
Tags
conferences
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) announced a virtual roadshow webinar scheduled for April 27, 2022, at 11:30 a.m. Eastern Time. The event will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt discussing recent company announcements and key milestones for 2022. Participants can join via a provided webcast link or dial-in numbers. A replay will be available for two months post-event. HeartBeam focuses on innovative ECG telemedicine technology aimed at enhancing heart attack detection for high-risk patients outside medical facilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.93%
Tags
conferences
-
Rhea-AI Summary

HeartBeam, a digital healthcare company focused on ECG telemedicine for heart attack detection, announced significant progress for Q4 2021, including partnerships for its Emergency Department (ED) myocardial infarction software and telehealth solutions. Key highlights include a $14.9 million IPO, new partnerships with LIVMOR Inc. and Phoebe Putney Health System, and an experienced leadership team poised for commercialization. The company ended 2021 with $13.2 million in cash, projecting sufficient funds into 2023, aiming for FDA submissions in 2022 and 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has entered a professional services agreement with Triple Ring Technologies for the development of a Telehealth 3D vector ECG collection device aimed at remote heart attack monitoring. This partnership will span five phases and is scheduled for FDA 510k submission in Q4 2022. The device is designed for patient use at home, providing crucial ECG data to physicians in real-time. With over 18 million people in the U.S. suffering from coronary artery disease, this innovative solution addresses a significant need in cardiac care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
partnership
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) will conduct a conference call on March 24, 2022, at 4:30 p.m. Eastern time to discuss its fourth quarter and full-year results for fiscal 2021, ending December 31, 2021. The call will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt. A press release with results will precede the call. Interested parties can join via phone or webcast. A telephone replay will be available until June 24, 2022. HeartBeam focuses on innovative ECG technology for heart attack detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
conferences

FAQ

What is the current stock price of Heartbeam (BEAT)?

The current stock price of Heartbeam (BEAT) is $1.69 as of April 4, 2025.

What is the market cap of Heartbeam (BEAT)?

The market cap of Heartbeam (BEAT) is approximately 58.0M.

What is HeartBeam Inc's primary business focus?

HeartBeam Inc specializes in high-resolution ambulatory ECG solutions and cloud-based diagnostic systems for remote cardiac monitoring. It combines portable hardware with advanced AI to enable accurate cardiac diagnostics outside of traditional healthcare settings.

How does the HeartBeam device compare to traditional ECG systems?

The HeartBeam device is designed to deliver a 12-lead equivalent ECG in a compact, credit card–sized format. Clinical studies have shown its diagnostic capabilities to be comparable to, and in some cases better than, conventional 12-lead ECG assessments conducted by cardiologists.

What role does AI and machine learning play in HeartBeam's technology?

AI and machine learning are integral to HeartBeam's diagnostic platform, continuously improving the system’s accuracy and predictive ability. These technologies analyze complex ECG data to refine diagnostic thresholds and support enhanced clinical decision-making.

What makes HeartBeam's technology clinically valuable?

The system’s clinical value lies in its ability to provide high-resolution, portable cardiac diagnostics validated by studies from Harvard Medical School. The integration of personalized diagnostic thresholds and novel ECG markers facilitates precise cardiac event location on 3D models.

How does HeartBeam ensure the accuracy of its diagnostics?

Accuracy is ensured through a combination of proprietary Vector ECG technology, rigorous clinical validation, and continual improvements driven by AI/ML algorithms. This multi-layered approach helps maintain high standards in diagnostic reliability.

What distinguishes HeartBeam from other telehealth and diagnostic companies?

HeartBeam distinguishes itself through its unique balance of portable hardware and sophisticated cloud-based analytics. Its innovative integration of advanced ECG technology, clinical validation, and AI-enhanced diagnostics sets it apart in the competitive digital health landscape.

In what environments can HeartBeam's technology be utilized?

The technology is suited for both clinical and out-of-hospital environments, enabling cardiac monitoring in ambulatory settings. Its portability and ease of use make it ideal for remote diagnostics and telehealth applications.

How does HeartBeam contribute to the advancement of digital cardiology?

By merging high-resolution diagnostic hardware with AI-driven data analysis, HeartBeam contributes to digital cardiology by providing more accessible, accurate, and efficient methods for diagnosing cardiac conditions. This innovation helps bridge the gap between traditional clinical assessments and modern telehealth practices.
Heartbeam Inc

Nasdaq:BEAT

BEAT Rankings

BEAT Stock Data

58.01M
26.15M
23.17%
7.89%
0.68%
Health Information Services
Surgical & Medical Instruments & Apparatus
Link
United States
SANTA CLARA